StockNews.com upgraded shares of Adicet Bio (NASDAQ:ACET – Free Report) to a sell rating in a research report released on Tuesday. Separately, Wedbush reissued an outperform rating and issued a $5.00 target price on shares of Adicet Bio in a report on Thursday, January 4th. One equities research analyst has rated the stock with a […]
StockNews.com upgraded shares of Adicet Bio (NASDAQ:ACET – Free Report) to a sell rating in a research report released on Tuesday. Separately, Wedbush reissued an outperform rating and issued a $5.00 target price on shares of Adicet Bio in a report on Thursday, January 4th. One equities research analyst has rated the stock with a […]
Adicet Bio, Inc. (NASDAQ:ACET – Free Report) – Stock analysts at Wedbush issued their FY2028 earnings per share (EPS) estimates for Adicet Bio in a research note issued to investors on Thursday, January 4th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of ($1.16) for the year. Wedbush has a […]
Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 3,030,000 shares, an increase of 6.7% from the October 31st total of 2,840,000 shares. Approximately 10.0% of the company’s stock are short sold. […]
Adicet Bio (NASDAQ:ACET – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Insider & Institutional Ownership 85.3% of Adicet […]